International Biotechnology Trust’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

International Biotechnology Trust’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,093	Closed	-$8.68M	–	84
2022 Q1	$8.68M	Sell	14,093 -47,648	-77%	-$1.6M	1.96%	20
2021 Q4	$2.94M	Sell	61,741 -77,000	-55%	-$3.44M	0.66%	36
2021 Q3	$9.22M	Buy	138,741 +17,200	+14%	+$1.23M	2.22%	15
2021 Q2	$9.48M	Buy	121,541 +40,000	+49%	+$2.96M	2.5%	14
2021 Q1	$7.71M	Sell	81,541 -32,000	-28%	-$3.81M	2.04%	18
2020 Q4	$13.8M	Buy	113,541 +78,541	+224%	+$8.6M	3.77%	12
2020 Q3	$3.05M	Hold	35,000	–	–	0.98%	24
2020 Q2	$2.24M	Hold	35,000	–	–	0.74%	27
2020 Q1	$1.54M	Hold	35,000	–	–	0.7%	27
2019 Q4	$2.18M	Buy	+35,000	New	+$1.67M	0.79%	32

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

International Biotechnology Trust's TPTX Position: Q2 2022 in Review

International Biotechnology Trust sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 14,093 shares — an estimated $8.68M sold.

International Biotechnology Trust first reported a position in TPTX in Q4 2019 and held it in 10 quarters. The position peaked at $13.8M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

International Biotechnology Trust reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
International Biotechnology Trust sold 14,093 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $8.68M.
International Biotechnology Trust first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
International Biotechnology Trust's Turning Point Therapeutics, Inc. Common Stock position peaked at $13.8M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.